SYRE
Spyre Therapeutics Inc.
NASDAQ: SYRE · HEALTHCARE · BIOTECHNOLOGY
$71.89
+4.75% today
Updated 2026-04-29
Market cap
$6.20B
P/E ratio
—
P/S ratio
650.22x
EPS (TTM)
$-1.98
Dividend yield
—
52W range
$12 – $75
Volume
1.1M
Spyre Therapeutics Inc. (SYRE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-7.33M | $-10.98M | $-18.84M | $-24.61M | $-32.19M | $-65.69M | $-75.78M | $-53.72M | $-80.14M | $-99.91M | $-157.41M | $-169.25M |
| Capital expenditures | $181000.00 | $208000.00 | $212000.00 | $619000.00 | $422000.00 | $1.49M | $4.28M | $573000.00 | $38000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | $19000.00 | $89000.00 | $132000.00 | $249000.00 | $293000.00 | $901000.00 | $996000.00 | $1.58M | $1.57M | $744000.00 | $744000.00 | — |
| Stock-based comp | $147000.00 | $767000.00 | — | — | — | $5.50M | $6.26M | $8.04M | $7.11M | $25.68M | $44.83M | $37.61M |
| Free cash flow | $-7.52M | $-11.19M | $-19.05M | $-25.23M | $-32.62M | $-67.18M | $-80.06M | $-54.29M | $-80.18M | $-99.91M | $-157.41M | $-169.25M |
| Investing cash flow | $-221000.00 | $-4.01M | $-12.16M | $-22.53M | $-15.23M | $-1.74M | $-7.60M | $-22.62M | $57.01M | — | $-353.29M | — |
| Financing cash flow | $5.58M | $41.67M | $49.37M | $12.21M | $57.07M | $65.72M | $154.51M | $1.39M | $42.68M | $361.08M | $410.91M | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — |